Overexpression of the multidrug efflux transport P-glycoprotein may play an important role in
pharmacoresistance. 11C-laniquidar is a newly developed tracer of P-glycoprotein …

Resistance to current drug therapy is an important issue in the treatment of epilepsy.
Inadequate access of central nervous system drugs to their targets in the brain may be …

The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in high concentrations at
the blood–brain barrier (BBB) and is believed to be implicated in resistance to central …

INTRODUCTION: An earlier report suggested that mass amount of PET tracers could be an
important factor in brain uptake mediated by P-glycoprotein. Thereby, this study investigated …

Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood–
brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain …

Objective XR9576 (tariquidar) is an anthranilic acid derivative and potent P-glycoprotein (P-
gp) inhibitor. XR9576 has undergone phase I and II studies as combined chemotherapy …

Abstract Organic Anion-Transporting Polypeptides (OATPs) are known to control the liver
uptake of many drugs. Non-hepatic expression of OATPs has been reported although …

At present, P-glycoprotein (P-gp) function can be studied using positron emission
tomography (PET) together with a labelled P-gp substrate such as (R)-[11C] verapamil. Such …

The adenosine triphosphate-binding cassette transporters P-glycoprotein (Pgp) and breast
cancer resistance protein (BCRP) are 2 major gatekeepers at the blood–brain barrier (BBB) …

The permeability-glycoprotein (P-gp) efflux transporter is densely expressed at the blood–
brain barrier, and its resultant spare capacity requires substantial blockade to increase the …